LA Times – Amgen Inc., the Southern California biotech giant that has struggled to match the torrid growth of its pharmaceutical peers, finds itself in the crosshairs of a New York hedge fund manager, one of the new breed of activist investors, who is loudly calling for the company to split in two.
Amgen is resisting a split, though by promising to shed thousands of jobs as part of a bid to boost its share price, it has been steadily giving in to Wall Street criticism of being bloated and inefficient.
